Exploring 3 High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has experienced a 1.7% drop, but it has shown resilience with a 3.6% rise over the past year and an anticipated annual earnings growth of 13%. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability in alignment with these positive long-term market trends.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 233 stocks from our US High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Bitdeer Technologies Group (NasdaqCM:BTDR)

Simply Wall St Growth Rating: ★★★★★★

Overview: Bitdeer Technologies Group is a technology company focused on blockchain and computing, with a market capitalization of $1.50 billion.

Operations: Bitdeer Technologies Group is engaged in blockchain and computing technology. The company generates revenue through its operations but specific revenue segments are not detailed in the provided information.

Despite recent operational challenges, Bitdeer Technologies Group demonstrates a robust commitment to innovation in the cryptocurrency mining sector. The company's recent unveiling of the SEAL03 chip, developed in partnership with TSMC, underscores its focus on enhancing power efficiency—a critical factor in sustainable mining operations. This advancement aligns with an impressive projected annual revenue growth rate of 42.4%, positioning Bitdeer favorably within the tech landscape. Moreover, the initiation of a share repurchase program worth $20 million reflects confidence in long-term value creation, further buoyed by forecasts suggesting profitability within three years and an expected earnings growth rate of 119.3% per annum. These strategic moves highlight Bitdeer's potential resilience and adaptability amidst fluctuating market conditions and technological evolutions.

• Unlock comprehensive insights into our analysis of Bitdeer Technologies Group stock in this health report.

• Examine Bitdeer Technologies Group's past performance report to understand how it has performed in the past.

Neurocrine Biosciences (NasdaqGS:NBIX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Neurocrine Biosciences, Inc. focuses on discovering, developing, and marketing pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders globally, with a market cap of approximately $10.04 billion.

Operations: The company generates revenue primarily through the research, development, and commercialization of pharmaceuticals, with reported revenues of $2.36 billion.

Neurocrine Biosciences has been making significant strides in the biotech sector, particularly with its focus on neurological and neuropsychiatric disorders. The recent appointment of Dr. Sanjay Keswani as CMO, coupled with successful Phase 2 studies for osavampator and NBI-1117568, underscores a robust pipeline poised for growth. Financially, the company reported a notable increase in annual revenue to $2.36 billion and net income of $341 million for 2024. These achievements are complemented by a strategic $500 million share repurchase program initiated in February 2025, signaling strong future prospects and confidence in sustained growth.

• Navigate through the intricacies of Neurocrine Biosciences with our comprehensive health report here.

• Review our historical performance report to gain insights into Neurocrine Biosciences''s past performance.

BeiGene (NasdaqGS:ONC)

Simply Wall St Growth Rating: ★★★★★☆

Overview: BeiGene, Ltd. is an oncology company focused on discovering and developing cancer treatments for patients across the United States, China, Europe, and other international markets with a market cap of $24.69 billion.

Operations: BeiGene generates revenue primarily through its pharmaceutical products, amounting to $3.81 billion. The company is engaged in the discovery and development of cancer treatments across multiple regions, including the United States, China, and Europe.

BeiGene, a company at the forefront of cancer treatment innovation, recently showcased its commitment to advancing B-cell cancer therapies through a strategic alliance with nference. This collaboration aims to enhance treatment paradigms for chronic lymphocytic leukemia and small lymphocytic lymphoma by analyzing over 700 patient charts. Additionally, BeiGene's TEVIMBRA® has been recommended by the CHMP for approval in Europe as a first-line treatment for extensive-stage small cell lung cancer, reflecting significant clinical advancements with a 25% reduction in death risk during trials. These developments underscore BeiGene’s pivotal role in transforming oncological care and highlight its potential influence on future medical treatments.

• Dive into the specifics of BeiGene here with our thorough health report.

• Learn about BeiGene's historical performance.

Turning Ideas Into Actions

• Investigate our full lineup of 233 US High Growth Tech and AI Stocks right here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com